BAX is a pro-apoptotic protein of the BCL-2 family that is stationed in the cytosol until activated by a diversity of stress stimuli to induce cell death. Anti-apoptotic proteins such as BCL-2 counteract BAX-mediated cell death. Although an interaction site that confers survival functionality has been defined for anti-apoptotic proteins, an activation site has not been identified for BAX, rendering its explicit trigger mechanism unknown. We previously developed stabilized a-helix of BCL-2 domains (SAHBs) that directly initiate BAX-mediated mitochondrial apoptosis. Here we demonstrate by NMR analysis that BIM SAHB binds BAX at an interaction site that is distinct from the canonical binding groove characterized for anti-apoptotic proteins. The specificity of the human BIM-SAHB-BAX interaction is highlighted by point mutagenesis that disrupts functional activity, confirming that BAX activation is initiated at this novel structural location. Thus, we have now defined a BAX interaction site for direct activation, establishing a new target for therapeutic modulation of apoptosis.
BAX is a pro-apoptotic protein of the BCL-2 family that is stationed in the cytosol until activated by a diversity of stress stimuli to induce cell death. Anti-apoptotic proteins such as BCL-2 counteract BAX-mediated cell death. Although an interaction site that confers survival functionality has been defined for anti-apoptotic proteins, an activation site has not been identified for BAX, rendering its explicit trigger mechanism unknown. We previously developed stabilized a-helix of BCL-2 domains (SAHBs) that directly initiate BAX-mediated mitochondrial apoptosis. Here we demonstrate by NMR analysis that BIM SAHB binds BAX at an interaction site that is distinct from the canonical binding groove characterized for anti-apoptotic proteins. The specificity of the human BIM-SAHB-BAX interaction is highlighted by point mutagenesis that disrupts functional activity, confirming that BAX activation is initiated at this novel structural location. Thus, we have now defined a BAX interaction site for direct activation, establishing a new target for therapeutic modulation of apoptosis.
The BCL-2 family comprises a network of pro-and anti-apoptotic proteins whose interactions regulate the critical balance between cellular life and death [1] [2] [3] . The family is structurally defined by the presence of up to four conserved 'BCL-2 homology' (BH) domains, all of which include a-helical segments 4 . Anti-apoptotic proteins such as BCL-2 and BCL-X L (also known as BCL2 and BCL2L1, respectively) show sequence conservation in three to four BCL-2 homology domains (BH1-4), whereas pro-apoptotic proteins are divided into multi-BCL-2 homology domain members such as BAX and BAK that contain three conserved domains (BH1-3) and 'BH3-only' members such as BIM (also known as BCL2L11) and BID that only show homology to the a-helical BH3 domain. The BH3only subgroup is diverse and transmits pro-death signals arising from disparate stimuli to the core apoptotic machinery located at the mitochondrion 5, 6 . Once deployed, the BH3 death signal is either neutralized by anti-apoptotic proteins or delivered to the mitochondrial executioners BAX and BAK, which on activation permeabilize the outer mitochondrial membrane 7, 8 . Released mitochondrial factors activate caspases that then implement the death program 9 .
Structural studies have established a survival mechanism for BCL-2 family interactions on the basis of sequestration of the a-helical BH3 death domain by a hydrophobic groove formed by the juxtaposition of the BH1-3 domains (BH1: portions of helices a4-a5; BH2: a7-a8; BH3: a2) of anti-apoptotic members 10 . The selective binding interactions of pro-apoptotic BH3 peptides and pro-apoptotic multi-BCL-2 homology domain proteins with anti-apoptotic BCL-2 family members have been well documented [11] [12] [13] [14] [15] [16] . The small molecules ABT-737 and ABT-263, constructed to selectively inhibit the anti-apoptotic proteins BCL-2 and BCL-X L by targeting the hydrophobic groove, reactivate apoptosis in select tumours 17, 18 . Thus, there is general agreement that one level of apoptosis regulation is mediated by the competitive interactions between pro-and anti-apoptotic members at the structurallydefined anti-apoptotic groove. However, what directly triggers BAX and BAK activation during apoptotic stress remains a matter of active debate 11, 13, 19 . Indeed, this lingering question concerning the biochemical mechanism that initiates BAX and BAK activation has recently been characterized as the ''holy grail of apoptosis research'' 3 .
BAX activation is believed to be a highly regulated, multi-step process involving an interaction-triggered conformational change, mitochondrial translocation and oligomerization that ultimately leads to mitochondrial dysfunction and apoptosis [20] [21] [22] [23] . A diversity of stimuli have been implicated in initiating BAX and BAK activation [24] [25] [26] , including direct involvement by select BH3 domains and BH3-only proteins 13, [27] [28] [29] [30] [31] [32] [33] [34] . To investigate the elusive initiating event for BAX activation, we studied the interaction of BAX with the BH3 ligand BIM SAHB, which we previously demonstrated recapitulates the a-helical character of native death domains and binds directly to BAX 33 . We report to our knowledge the first structural analysis of a BH3 a-helix bound to a full-length proapoptotic multi-BCL-2 homology domain protein, unveiling a previously unknown site of protein interaction for functional activation and pharmacological modulation of BAX ( Supplementary Fig. 1 ).
Identification of a BH3 interaction site on BAX
BIM SAHB binding to BAX was monitored using NMR spectroscopy. Compared to the 1 H-15 N heteronuclear single quantum coherence (HSQC) spectrum of BAX, the addition of BIM SAHB broadened and shifted select NMR cross-peaks, indicating fast exchange between the bound and unbound conformations of BAX. The overall features of the NMR spectra are quite similar except for significant changes in the loop residues between a1 and a2 on BIM SAHB binding. Chemical shift perturbation mapping of BAX with BIM SAHB titration revealed interactions at a discrete subset of BAX residues. The degree of change in the 1 H-15 N cross-peak positions for backbone amides is shown in Fig. 1a . The largest changes were observed for residues located in the a1 and a6 helices, as well as residues in the flexible loop between a1 and a2. Significant changes were also observed for the side-chain NH 2 of Q28, Q32 and Q52 ( Supplementary Fig. 2 ). In the BAX structure 35 , the a1 and a6 helices are positioned adjacent to one another, and the residues affected by BIM SAHB binding localize to a discrete site at the juxtaposition of these a-helices on one side of the protein structure ( Fig. 1b ). Of note, no residues on the carboxy-terminal side of the protein are affected by BIM SAHB titration under these conditions, thus placing the novel binding site on the completely opposite face of the protein from the canonical BH3 binding site of anti-apoptotic proteins ( Supplementary Fig. 1 ). The binding site of BIM SAHB on BAX is thus defined by the two helices a1 and a6, with the interhelical junction forming a hydrophobic cleft surrounded by a perimeter of hydrophilic and charged residues ( Fig. 1c ).
Orientation of BIM SAHB at the BAX site One of the challenges of capturing a BAX-activating interaction by NMR is time-and dose-dependent BAX aggregation due to BIM SAHB addition to the NMR sample. With time, the size of the protein aggregate formed leads to line broadening of the NMR resonances beyond detection, thereby precluding acquisitions of data for the duration required to resolve the initial complex by conventional NMR. Nevertheless, to orient BIM SAHB at the BAX interaction site, we conducted paramagnetic relaxation enhancement (PRE) NMR experiments, which can be performed on a timescale that is compatible with the lifespan of the complex under NMR conditions. 1 H-15 N HSQC spectra of BAX, were acquired with methane thiosulphonate (MTSL)derivatized BIM SAHBs ( Fig. 2a ) in the oxidized state and then repeated after nitroxide reduction. Of note, the chemical shift perturbation maps of BAX in complex with BIM SAHB and the MTSL-labelled derivatives demonstrate consistent changes in BAX helices a1 and a6, and in the a1-a2 loop ( Supplementary Fig. 3 ). Whereas the intensity of BAX a1 residues are predominantly reduced in the presence of an oxidized C-terminal label, the intensity of BAX a6 residues are predominantly decreased by the presence of an oxidized amino-terminal label (Fig. 2b) . As an example, BIM SAHB(A164C-MTSL) caused marked signal suppression of S16 (a1) but had essentially no effect on D142 (a6) ( Supplementary Fig. 4a ), whereas BIM SAHB(W147C-MTSL) had no effect on S16 (a1) but reduced the D142 (a6) signal ( Supplementary Fig. 4b ). Because the degree of PRE correlates with the distance between the nitroxide label and the affected BAX residues 36 , structure calculations using restraints derived from PRE and chemical shift perturbation data were performed to define the orientation of BIM SAHB at the new BAX site. The calculated model structures converged to place BIM SAHB perpendicular to BAX helices a1 and a6, with the N to C terminus directionality of the peptide disposed right to left ( Fig. 2c and Supplementary Table 1 ). Whereas the location of the BAX binding site is geographically distinct, the calculated model structure of the BIM-BH3-BAX complex shows an interaction topography that is notably similar to that of BIM BH3 with anti-apoptotic BCL-X L , MCL1 and BFL1/A1 (also known as BCL2A1), as previously determined by X-ray crystallography ( Supplementary Fig. 5 ).
Initiation of BAX activation by BIM SAHB
In contrast to the stable inhibitory interactions of BIM BH3 with anti-apoptotic proteins, the BAX-activating interaction triggers a dynamic continuum of events that includes BAX conformational change and oligomerization ( Supplementary Fig. 6 ). Of particular interest, NMR resonances of residues in the a1-a2 loop of BAX shifted significantly on BIM SAHB binding ( Fig. 1a and Supplementary Fig. 3 ). In monomeric BAX, the centre of the loop weakly associates with residues I133 and M137 of the a6 helix 35 . Changes observed in the loop residues can readily be explained by the shift of the loop conformation into an open form on BIM SAHB binding. Because loop displacement on ligand engagement may initiate a conformational change of BAX, we investigated whether BIM SAHB binding could directly activate BAX in solution. We monitored both the conversion of BAX from monomer to oligomer by size-exclusion chromatography (SEC) and the exposure of its buried N-terminal residues using the 6A7 antibody, which selectively detects the conformational change associated with BAX activation 37 . Indeed, BIM SAHB triggered dose-dependent oligomerization of BAX (Fig. 3a) . This BIM-SAHB-induced oligomerization correlated with exposure of the N-terminal epitope of BAX as recognized by the 6A7 antibody (Fig. 3b) . Thus, the transient stability of the BIM-SAHB-BAX complex we observe by NMR correlates with the interactiontriggered BAX conformational change and oligomerization that we detect biochemically.
To confirm that the SEC-based detection of BIM-SAHB-induced BAX oligomerization reflects functional activation of BAX for its release activity, we performed correlative liposomal and mitochondrial assays. In liposomal assays that explicitly explore the capacity of BIM SAHB to directly trigger functional BAX activation in the absence of other factors, the combination of BIM SAHB and BAX yielded dose-responsive liposomal release of entrapped fluorescein isothiocyanate (FITC)-dextran ( Fig. 3c) . Similarly, in mitochondrial release assays that used BAX-and BAK-deficient mouse liver mitochondria prepared from Alb-cre pos Bax flox/2 Bak 2/2 mice, BIM SAHB induced dose-responsive BAX-mediated cytochrome c release ( Fig. 3d ). Thus, in four distinct in vitro assays that measure ligandinduced BAX activation, BIM SAHB directly and dose-responsively activated BAX. 
Specificity of BIM-SAHB-induced BAX activation
We next performed a 'staple scan' and mutagenesis studies to demonstrate and link the specificity of BIM-SAHB-induced BAX activation to interaction at the new site. By performing a staple scan that effectively replaces pairs of amino acid residues within the core BH3 sequence with crosslinked norleucine-like side chains, we simultaneously addressed which residues are essential to the functional interaction between BIM BH3 and BAX, and further confirm which surface along the BIM BH3 a-helix is essential to BAX engagement (Fig. 4a ). Substituting the nonnatural amino acid at positions W147, A149, E151, R153, R154, E158 or Y162 did not disrupt BIM-SAHB-induced BAX oligomerization (Fig. 4b) or BAX-mediated cytochrome c release ( Fig. 4c and Supplementary Fig. 7a ). Indeed, hydrocarbon staples located along the length of the a-helix at surfaces that do not face the hydrophobic contact site on BAX did not disrupt the functional interactions between the BIM SAHB analogues and BAX. However, a staple position that replaced I148 and the highly conserved L152, and localizes to the hydrophobic contact surface for BAX on the BIM BH3 a-helix ( Fig. 4a ), markedly decreased both BAX oligomerization ( Fig. 4b) and BAXmediated cytochrome c release ( Fig. 4c and Supplementary Fig. 7a ), findings which are consistent with the near abrogation of BIM-SAHBinduced chemical shift perturbations of 15 N-BAX by BIM SAHB C ( Supplementary Fig. 8a ). In addition, BAD SAHB A (ref. 33 ), which has the identical staple position as BIM SAHB A but otherwise contains a distinct amino acid sequence, did not bind ( Supplementary Fig. 8b ) or oligomerize ( Fig. 4b ) BAX, or induce BAX-mediated cytochrome c release ( Fig. 4c and Supplementary Fig. 7a ).
To further examine ligand specificity, we generated and screened a panel of BIM SAHBs bearing single amino acid mutations within the core BH3 consensus sequence, including I155E, R153D and D157R ( Fig. 4d and Supplementary Fig. 5a ). In each case, point mutagenesis abolished BIM-SAHB-induced BAX oligomerization ( Fig. 4e) and BAX-mediated cytochrome c release ( Fig. 4f and Supplementary  Fig. 7b ), indicating that interference with principal hydrophobic or charge interactions specifically disrupts BIM SAHB engagement of the new BAX site.
Mutagenesis of the BAX site impairs activation
To examine the effect of BAX mutagenesis at the a1-a6 interaction site, we mutated residue K21, which exhibited the most pronounced chemical shift on BIM SAHB binding (Fig. 1a) . We generated recombinant BAX bearing a K21E point mutation ( Supplementary Fig. 9 ) and observed that BIM-SAHB-induced BAX(K21E) activation was significantly reduced compared to wild-type BAX as measured by the oligomerization assay (Fig. 5a ). BAX(K21E)-mediated cytochrome c release in response to BIM SAHB was likewise blunted (Fig. 5b) . To determine whether this single amino acid mutation within the BAX binding site affected the capacity to activate BAX in a cellular context, we retrovirally reconstituted Bax 2/2 Bak 2/2 mouse embryonic fibroblasts (DKO MEFs) with either wild type or BAX(K21E) and monitored apoptosis induction in response to BIM SAHB. Whereas BIM SAHB induced time-dependent apoptosis of BAX-reconstituted MEFs, as quantified by annexin V binding, a single K21E point mutation within the BAX binding site reduced BIM-SAHB-triggered apoptosis (Fig. 5c ). This decrease in BAX(K21E)mediated apoptosis correlates with impaired activation of BAX(K21E) by BIM SAHB in both oligomerization and cytochrome c release assays (Fig. 5a, b) . As a further measure of specificity, we a-c, BIM SAHBs with differential staple positions (a) and their activities in BAX oligomerization (b) and BAX-mediated cytochrome c release assays (c). In the sequence in a, X is a stapling amino acid, B is norleucine. d-f, BIM SAHB A point mutants (d) and their activities in BAX oligomerization (e) and BAX-mediated cytochrome c release assays (f). Data are mean and s.d. NATURE | Vol 455 | 23 October 2008 found that R153D mutagenesis of BIM SAHB, which eliminated its BAX activating capacity in the oligomerization and cytochrome c release assays (Fig. 4e, f) , similarly abolished BIM-SAHB-induced activation of BAX and BAX(K21E) in a cellular context (Fig. 5c ).
To probe the broader physiological effect of the new BAX activation site, we examined the apoptotic response of DKO MEFs reconstituted with BAX or BAX(K21E) to staurosporine (STS), a general stimulus known to operate through endogenous BH3-only proteins 13, 38 , including BIM 39 . K21E mutagenesis impaired STS-induced apoptosis, as monitored by annexin V binding over time (Fig. 5d ). The reduced activity of BAX(K21E) was also reflected by impaired cytochrome c release, as detected by subcellular fractionation western analysis and indirect immunofluorescence ( Supplementary Fig. 10 ). The blunted response of BAX(K21E)-reconstituted DKO MEFs to STS is uniformly consistent with impaired activation of BAX(K21E) by BIM SAHB in oligomerization (Fig. 5a ), cytochrome c release ( Fig. 5b ) and cell-based apoptosis assays (Fig. 5c ). Thus, the MEF studies extend the mechanistic relevance of direct BAX activation to a cellular context in which BAXmediated apoptosis is impaired by single amino acid mutagenesis at the previously unknown BH3 interaction site. Taken together, the in vitro and cell-based mutagenesis experiments highlight the exquisite specificity of the BIM-BH3-BAX interaction and implicate engagement of the novel binding site as a trigger mechanism for initiating BAX activation.
Discussion
Our data now define an explicit binding site on BAX for BH3 engagement that directly initiates BAX activation. In contrast to the constitutive mitochondrial localization of pro-apoptotic BAK, BAX is predominantly cytosolic, thereby necessitating a trigger mechanism for its activation and translocation to the mitochondria to induce mitochondrial outer membrane permeabilization 40 . The C-terminal a-helix of BAX folds back into its hydrophobic cleft 35 , which is homologous to the BH3-binding anti-apoptotic groove 10, 41 ( Supplementary  Fig. 1 ). The amphipathic nature of the C-terminal a-helix of BAX enables the hydrophobic face to closely interact with the canonical hydrophobic groove, whereas the hydrophilic face promotes solubility by readily engaging the aqueous environment. In order for BAX to insert into the outer mitochondrial membrane during targeting, the C-terminal a-helix must be dislodged, presumably coinciding with an induced global protein conformational change 35 (Supplementary Fig.  6 ). Although the structural characteristics of this conformational change are unknown, the N and C termini of BAX have been implicated in locking down cytosolic BAX until structural reorganization and mitochondrial targeting are initiated 21, 37, [42] [43] [44] . Here we report, to our knowledge, the first structural identification of a distinct BH3 binding site on BAX comprised of helices a1 and a6. Indeed, our findings support a previous observation that the first a-helix of BAX participates in an interaction with the BH3 domains of BID and PUMA (also known as BBC3), as demonstrated by yeast two-hybrid and coimmunoprecipitation analyses 27 . We find that BIM SAHB engagement directly triggers the functional activation of BAX. Furthermore, BAX activation is specifically disrupted by mutagenesis of the new interface. These data indicate that BAX can be directly targeted by a BH3 domain at a site that is geographically distinct from but markedly similar in topography to the canonical anti-apoptotic groove, and can thereby unleash the pro-apoptotic activity of BAX.
Structural reorganization to achieve functional activity is a unifying feature of BCL-2 family proteins, and for a subset of pro-and antiapoptotic members, translocation from the cytosol to organelle compartments is also essential 21, 23, 35, 40, 45 . Our identification of a BH3 ligand binding site on BAX suggests that engagement of alternative BCL-2 family binding sites may have important roles in regulating apoptotic protein structure, intracellular localization and functional activation. Whereas blockade of the new site may effectively repress BAX-induced cell death, ligand engagement may trigger BAX-mediated apoptosis. Thus, our identification of a previously unknown BAX activation site has important implications for the development of pharmacological agents to respectively activate or inhibit apoptosis in human diseases characterized by unrestrained cell survival or pathological cell death.
METHODS SUMMARY
SAHBs were synthesized using our established method 46, 47 and recombinant BAX for NMR and biochemical analyses was generated as previously described 33, 35 . Samples for HSQC and PRE NMR contained uniformly 15 Nlabelled BAX at 0.2 mM prepared in 10 mM sodium acetate solution at pH 6.0 with up to a 1:1 molar ratio of SAHB. NMR spectra were acquired at 32 uC on Bruker 600 and 800 MHz spectrometers, and then processed and analysed as described in the Methods. To evaluate BIM-SAHB-induced BAX activation, four in vitro assays were performed. The oligomerization assay used freshly purified monomeric BAX in combination with BIM SAHB at the indicated ratios and incubation durations followed by size-exclusion chromatography to quantify monomeric versus oligomeric BAX. The BAX conformational change assay also used the indicated BIM-SAHB:BAX mixtures, which were exposed to the conformation-specific 6A7 anti-BAX antibody, followed by immunoprecipitation and BAX western analysis to monitor the proportion of activated conformer of BAX on BIM SAHB exposure. To determine whether the BIM-SAHB-induced BAX conformational change reflected functional activation of its release activity, we conducted liposomal and mitochondrial release assays as previously described 33, 48 and using the indicated doses and constructs of BIM SAHB and BAX. For cellular studies, DKO MEFs were reconstituted with BAX by retroviral transduction of BAX-IRES-GFP as previously reported 7, 13 and as described in the Methods. BAX or BAX(K21E)-reconstituted DKO MEFs were exposed to either BIM SAHBs or staurosporine, and cell death was quantified over time by annexin-V-Cy3 binding followed by flow cytometric analysis.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. 
